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Objective. To assess the eﬀect of sulfotanshinone sodium injection for unstable angina. Methods. We searched for published
and unpublished studies up to June 2011. We included randomized controlled trials that confoundedly addressed the eﬀect of
sulfotanshinone sodium injection in the treatment of unstable angina. Results. Twenty-ﬁve studies involving 2,377 people were
included. There was no evidence that sulfotanshinone sodium alone had better or worse eﬀects to routine western medicine
treatments in improving clinical symptoms (RR 1.00, 95% CI 0.90 to 1.11) and ECG (RR 0.97, 95% CI 0.87 to 1.09). However,
there was evidence that sulfotanshinone sodium combined with western medications was a better treatment option than western
medications alone in improving clinical symptoms (RR 1.28, 95% CI 1.23 to 1.3), ECG (RR 1.26, 95% CI 1.18 to 1.35), C-reaction
protein (mean diﬀerence 2.10, 95% CI 1.63 to 2.58), and IL-6 (mean diﬀerence −3.85, 95% CI −4.10 to −3.60). There was no
diﬀerence between sulfotanshinone sodium plus western medications and western medications alone aﬀecting mortality (RR
0.50, 95% CI 0.02 to 12.13). Conclusion. Compared with western medications alone, sulfotanshinone sodium combined with
western medications may provide more beneﬁts for patients with unstable angina. Further large-scale high-quality trials are
warranted.
1.Introduction
Coronary artery disease is the leading cause of death in the
United States [1]. Early hospital care for unstable angina
includes anti-ischemic therapies, antiplatelet therapies, and
anticoagulant/antithrombotic therapies and may also con-
sider an early invasive strategy [2]. Thrombolytic agents are
usually more frequently used for more severe conditions [3–
5].
Danshen, also known as Salvia miltiorrhiza Bge,i sa
hemorheologic agent that may have protective eﬀect in
patients with unstable angina [6] and has been used for
cardiovascular disorders for hundreds of years in China and
now is widely used in other countries as well.
Danshen consists of a mixture of compounds, among
which Tanshinone IIA (TIIA) represents the most biolog-
ically active ingredient [7]. TIIA, also known as Danshen
ketone, Tanshinon II, Tanshinone B, is a diterpenoid naph-
thoquinone extracted and isolatedderivative from Danshen.
Animal and cellular studies have shown various potential
beneﬁts of the agent, including (1) neuroprotective eﬀect
in cerebral ischemia and reperfusion [8], (2) antioxidant
potential to prevent oxidation of low-density lipoproteins
[9], (3) ability of rescuing PC-12 cells from hypoxia [10], (4)
reducing cellular damage by free radicals [11], (5) protecting
mitochondrial membrane from ischemia-reperfusion injury
and lipid peroxidation [12], (6) decreasing PHB expression
in oxidative stress-injured myocardial cells hence protecting2 Evidence-Based Complementary and Alternative Medicine
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Figure 1: PRISMA ﬂow chart of literature retrieval and selection.
SS Routine Risk ratio Risk ratio Study or subgroup
Events Total Events Total Weight M-H, ﬁxed, 95% CI M-H, ﬁxed, 95% CI
Zhao 2007 37 39 37 39 100% 1 [0.90, 1.11]
Total (95% CI) 39 39 100% 1 [0.90, 1.11]
Heterogeneity: not applicable
Favors routine Favors SS
0.5 0.7 1 1.5 2
Test for overall eﬀect: Z = 0( P = 1)
Figure 2: SS versus Isosorbide, outcome: clinical symptom improvement.
the myocardial cells [13], (7) protecting cardiomyocytes
against oxidative stress-mediated apoptosis [14], and (8)
cardioprotective in the context of diabetic cardiomyopathy
through kinin B2 receptor-Akt-GSK-3β-dependent pathway
[15]. Human studies also have demonstrated cardioprotec-
tive eﬀects of TIIA, including reduction of myocardial infarct
size and decrease of myocardial consumption of oxygen [16].
Until now, the clinically available TIIA agent, which is
approved by State Food and Drug Administration of China,
only includes sulfotanshinone sodium (SS) injection (i.e.,
sodiumtanshinoneIIAsulfonateinjection)manufacturedby
twocompanies.TIIAisextractedfromtherawherbDanshen
and then chemically derivatized into water-soluble SS for
the preparation of injection. Upon the administration of SS
injection, SS transforms back into the bioactive ingredient
TIIA in vivo [17]. The dosage for administration of SS
injection is 40–80mg per day. SS injection is given diluted
at the point of treatment in 20mL 25% glucose injection for
intramuscular administration or in 250–500mL 5% glucose
injection for intravenous administration. It is widely used in
the Chinese hospitals for unstable angina [18].
However, the eﬀects of SS injection on unstable angina
havenotbeenwellestablished.Inthisstudy,weevaluatedthe
eﬀect of SS through a rigorous systematic review and meta-
analysis of randomized trials.
2. Methods
2.1. Eligibility Criteria. We included randomized controlled
trials that compared SS with placebo or active agents in
patients with unstable angina deﬁned as new onset (≤2Evidence-Based Complementary and Alternative Medicine 3
Table 1: Randomized controlled trials of SS injection for unstable angina pectoris.
Study Method N (M:F) Mean age Interventions Outcomes
Zhao 2007 [19] RCT, not blinded
Duration: 2W 78 (54:24) 62.8
(1) Isosorbide mononitrate
40mg
(2) SS 40mg
(1) clinical symptom
improvement, (2) ECG, (3)
frequency, duration and
intervals of angina attacks
Yan et al. 2009
[20]
RCT, not blinded
Duration: 4W 94 (53:41) 52
(1) Routine (Aspirin
300mg–100mgqd, Enoxaparin,
Elantan 50mg, Betaloc 100mg)
(2) Routine + SS 60mg
(1) clinical symptom
improvement, (2) ECG, (3)
FIB, (4) D-dimer
Wang and Hou
2010 [21]
RCT, not blinded
Duration: 2W 100 (65:35) 62
(1) Routine (Aspirin, Nitrates,
Calcium antagonists, Ozagrel)
(2) Routine + SS 40mg
(1) clinical symptom
improvement, (2) ECG
Yang et al. 2010
[13, 22]
RCT, not blinded
Duration: 1W 64 (35:39) 59
(1) Routine (Aspirin 100mgqd,
Isosorbide mononitrate 20mg
bid, Metoprolol 25mg bid)
(2) Routine + SS 60mg
(1) clinical symptom
improvement, (2) ECG, (3)
C-reaction protein, (4)IL-6,
(5) plasma viscosity, (6)
FIB
Ge et al. 2010
[23]
RCT, not blinded
Duration: 15D 60 (39:21) 58
(1) Routine (Nitrates, Betaloc,
anticoagulant and antiplatelet
aggregation medication, ACEI,
Statins)
(2) Routine + SS 60mg
(1) clinical symptom
improvement, (2) ECG, (3)
TC, TG, LDL-C, HDL-C
Ge and Zhu
2009 [24]
RCT, not blinded
Duration: 2W 48 (32:16) 40–80Range
(1) Routine (Aspirin, Betaloc,
ACEI, Calcium antagonists,
Isosorbide mononitrate,
antiplatelet agents,
Trimetazidine)
(2) Routine + SS 50mg
(1) clinical symptom
improvement.
Hu et al. 2009
[25]
RCT, not blinded
Duration: 2W 148 60
(1) Routine (Statins, ARB, ACEI,
Nitrates, Aspirin, LMWH,
Betaloc)
(2) Routine + SS 40mg
(1) clinical symptom
improvement, (2) ECG.
Pei and Chen
2009 [26]
RCT, not blinded
Duration: 2W 71 (48:23) 65
(1) Routine (Aspirin,
Clopidogrel, LMWH, Nitrates,
Betaloc, Statins,
nondihydropyridine calcium
antagonists)
(2) Routine + SS 40mg
(1) clinical symptom
improvement, (2) plasma
viscosity, (3) blood
viscosity at high/low shear
stress, (4) hematocrit.
Zuo and Hou
2009 [27]
RCT, not blinded
Duration: 2W 83 (58:25) 72
(1) Routine (Aspirin, Betaloc,
Nitrates, Statins, LMWH)
(2) Routine + SS 40mg
(1) clinical symptom
improvement, (2) length of
angina from attacking to
alleviating, (3) length of
angina from attacking to
vanishing, (4) times of
myocardial ischemia onset.
Song 2008 [28] RCT, not blinded
Duration: 2W 105 72
(1) Routine (Aspirin,
Simvastatin, Betaloc, Nitrates,
Diltiazem, ARB, ACEI)
(2) Routine + SS 60mg
(1) clinical symptom
improvement.
Xu and Su 2008
[29]
RCT, not blinded
Duration: 1W 74 (40: 30) 45–78Range
(1) Routine (Fluvastatin, Aspirin,
Betaloc, LMWH)
(2) Routine + SS 80mg
(1) C-reaction protein, (2)
IL-6, (3) P-selectin, (4)
PAI-1
Huang et al.
2008 [30]
RCT, not blinded
Duration: 2W 220 (140:80) 62
(1) Routine (LMWH, Betaloc,
Isosorbide mononitrate, calcium
antagonists, Statins, Aspirin)
(2) Routine + SS 60mg
(1) clinical symptom
improvement, (2) ECG, (3)
plasma/whole blood
viscosity, (4)
systolic/diastolic blood
pressure, (5) heart rate, (6)
hematocrit, (7) Platelet
aggregation, (8) FIB.4 Evidence-Based Complementary and Alternative Medicine
Table 1: Continued.
Study Method N (M:F) Mean age Interventions Outcomes
Li et al. 2008
[31]
RCT, not blinded
Duration: 2W 125 (80:45) 62.41
(1) Routine (ACEI, vasodilator,
antiplatelet agents,
anticoagulants)
(2) Routine + SS 60mg
(1) NO, (2) FMD, (3) ET.
Hua et al. 2007
[32]
RCT, not blinded
Duration: 2W 112 (69:43) 60
(1) Routine (Aspirin, LMWH,
Betaloc, Nitroglycerin, ACEI,
Isosorbide mononitrate)
(2) Routine + SS 80mg
(1) clinical symptom
improvement, (2) ECG, (3)
plasma viscosity, (4) whole
blood viscosity,
(5) erythrocyte
aggregation, (6) morality,
(7) FIB.
Wang et al. 2007
[33]
RCT, not blinded
Duration: 2W 50 (28:22) 48.5
(1) Routine (Betaloc, Isosorbide
mononitrate, Diltiazem, Aspirin)
(2) Routine + SS 50mg
(1) clinical symptom
improvement, (2) ECG, (3)
D-dimer, (4) C-reaction
protein, (5) plasma
viscosity, (6) erythrocyte
aggregation, (7)
hematocrit.
Ma et al. 2007
[34]
RCT, not blinded
Duration: 2W 59 (37:22) 62.7
(1) Routine (Betaloc, Aspirin,
ACEI, Isosorbide mononitrate,
calcium antagonists,
anticoagulants,)
(2) Routine + SS 40mg
(1) clinical symptom
improvement, (2) ECG, (3)
morality.
X. G. Zhang and
Y. M. Zhang
2006 [35]
RCT, not blinded
Duration: 4W 60 (33:27) 62
(1) Routine (antiplatelet agents,
Nitrates, Betaloc, ACEI,
Diuretics)
(2) Routine + SS 60mg
(1) clinical symptom
improvement, (2) ECG, (3)
systolic/diastolic blood
pressure, (4) heart rate, (5)
frequency and duration of
angina attacks, (6)
Premature ventricular
contractions in 24 hours.
Zhang et al.
2006 [36]
RCT, single blinded
Duration: 2W 52 —
(1) Routine (Nitrates, Betaloc,
Aspirin)
(2) Routine + SS 80mg
(1) clinical symptom
improvement, (2) ECG.
Liu and Yang
2010 [37]
RCT, not blinded
Duration: 2W 100 (61:49) 65
(1) Routine (LMWH 6000U
q12h, Nitrates, Simvastatin
2 0m gq n ,B e t a l o c ,A C E I ,
Aspirin)
(2) Routine + SS 50mg
(1) clinical symptom
improvement.
Yang and Cai
2009 [38]
RCT, not blinded
Duration: 4W 64 (32: 32) 49.5
(1) Routine (Captopril 25mgqd,
Betaloc 25mg bid, Isosorbide
mononitrate 40ragqd, Aspirin
0.1gpd, Simvastatin 25rag, qn)
(2) Routine + SS 60mg
(1) clinical symptom
improvement, (2) ECG, (3)
frequency and duration of
angina attacks.
Bai and Ding
2007 [39]
RCT, not blinded
Duration: 4W 80 (42:38) 61
(1) Routine (Nitrates, Betaloc,
ACEI, antiplatelet agents,
LMWH)
(2) Routine + SS 80mg
(1) clinical symptom
improvement, (2) ECG.
Fang and Wang
2007 [40]
RCT, not blinded
Duration: 10D 120 (54:66) 74
(1) Routine (LMWH 5000U,
Nitroglycerin 10mg)
(2) Routine + SS 60mg
(1) clinical symptom
improvement.
Jiang 2004 [41] RCT, not blinded
Duration: 3W 156 (82:74) 60.9 (1) Routine (ACEI, Betaloc)
(2) Routine + SS 40mg
(1) clinical symptom
improvement, (2)
C-reaction protein, (3)
times of angina attacks
daily.
Qi and Qu 2008
[42]
RCT, not blinded
Duration: 2W 68 (38:30) 63 (1) Routine (Nitrates, Aspirin)
(2) Routine + SS 60mg
(1) frequency of angina
attacks, (2) duration of
angina attacks, (3) TC, TG,
HDL, LDL.Evidence-Based Complementary and Alternative Medicine 5
Table 1: Continued.
Study Method N (M:F) Mean age Interventions Outcomes
Han and Wang
2011 [43]
RCT, not blinded
Duration: 2W 186 (94:92) 55
(1) Routine (nitroglycerin
20mg)
(2) Routine + SS 60mg
(1) clinical symptom
improvement.
RCT: randomized clinical trial; F: female; M: male; W: week(s); D: day(s); 1: control group; 2: trial group; SS: SS; LMWH: Low molecular weight heparin;
ACEI: angiotensin-converting enzyme inhibitors; ARB: angiotensin receptor blocker; TC: total cholesterol; TG: Triglyceride; HDL: high density lipoprotein;
LDL: low density lipoprotein; NO: nitric oxide; FMD: ﬂow-mediated dilation; ET: endothelin; FIB: ﬁbrinogen; qd: once per day; qn: once per night; bid:t wi c e
per day; q12h: once every 12 hours.
months) exertional angina of at least Canadian Cardio-
vascular Society Classiﬁcation (CCSC) class III in severity,
signiﬁcant recent increase in frequency and severity of
angina, or angina at rest.
The eligible comparisons include
(i) SS injection versus any current western medications,
(ii) SS injection plus any current western medications for
unstable angina versus western medications alone,
(iii) SS injection versus placebo.
Our prespeciﬁed primary outcome is all-cause mortality,
and secondary outcomes include resolution of angina, ECG
improvement, inﬂammatory factors (such as C-reaction
protein and IL-6), and adverse events. The improvement
of clinical symptoms is measured as the reduction in chest
pain and shortness of breath or the frequency, severity,
and length of acute angina attacks. “Very eﬀective” includes
that there is no angina attack, chest pain disappears, ST
segment depression is back to normal, or the depression
of ST segment reduces >0.1mV; “eﬀective” includes that
times of angina attacks reduce by >2/3 or the length,
frequency, and severity of angina attacks and chest pain
signiﬁcantly reduce, the depression of ST segment reduces
<0.1mV but >0.05mV; “ineﬀective” includes that there
is no change or very little change in chest pain and
shortness of breath, or the frequency, severity and length of
acute angina attacks, the depression of ST segment reduces
<0.05mV. For the systematic review, the outcomes of both
“very eﬀective” and “eﬀective” were considered successful
treatments.
2.2. Search Strategy. We searched the Cochrane Library
(Issue 7, 2011), Chinese Cochrane Centre Controlled Trials
Register (to June 2011), Medline (1995 to June 2011),
EMBASE (1995 to June 2011), CNKI database (1979 to
June 2011), Wanfang Data (1998 to June 2011), and VIP
Information (1985 to June 2011) using the following key
words: unstable angina, angina, SS, tanshinone IIA, and
sodium tanshinone IIA sulfonate, as well as the brand names
of the agent. We also searched databases of ongoing trials,
including Current Controlled Trials and the UK National
Research Register.
We also searched Chinese medicine journals not indexed
in the electronic databases. We screened the reference lists of
relevant trials and identiﬁed reviews. We contacted experts
in this ﬁeld and relevant pharmaceutical companies for
additional references or unpublished studies. We restricted
the language of publications to English and Chinese.
2.3.DataCollection. Tworeviewers(QiuandYang)indepen-
dently screened the titles, abstracts, and key words of each
searched article for potentially eligible studies. Reviewers
then screened full texts for ﬁnal eligibility. The full-text arti-
cles were retrieved for further assessment if the information
given suggests that the study: (1) included patients with
unstable angina, (2) compared SS injection with western
medication in the presence or absence of cointerventions
in both groups, (3) assessed one or more relevant clinical
outcome measure such as morality, clinical symptoms, or
electrocardiogram (ECG), (4) had clearly outlined criteria
for successful treatment and treatment success was not
measured in terms of illness severity scores or the intensity
of individual symptoms, and (5) used random allocation.
Reviewers independently extracted data from eligible
studies, using pilot-tested data extraction forms. Reviewers
extracted the following data: age and number of participants
in the SS group and the control group, male-female ratio
in each group, diagnosis criterion, treatment dosage and
duration, side eﬀects, and symptoms that improved after
treatments. Important missing data were obtained by con-
tacting article authors whenever possible.
We excluded studies if they (1) included nonunstable
angina, used or compared with other Chinese Medicine,
(2) used diﬀerent routine western medications in the trial
group and control group, (3) were not randomized trials, (4)
had unclear criteria of symptom improvement or data error,
(5) were duplicated, or (6) were not conducted on human
subjects.
2.4. Risk of Bias. Two reviewers (Qiu and Yang) indepen-
dently assessed the risk of bias for each trial according to the
CochraneHandbookforSystematicReviewsofInterventions
version 5.1.0 [44]. The items included the random sequence
generation, allocation concealment, blinding, incomplete
outcome data, selective outcome reporting, and other poten-
tial threats to validity. Summary assessments of the risk
of bias for important outcomes within and across studies
was made. Based on Cochrane handbook [44] ,as t u d yi s
considered at low risk of bias if there is low risk of bias for
all key domains within a study; it is considered to be unclear
risk of bias if unclear risk of bias is for one or more key
domains within studies at unclear risk of bias across studies;
it is considered to be high risk of bias if high risk of bias for6 Evidence-Based Complementary and Alternative Medicine
Table 2: Assessment of risk of bias in included studies.
Study
Random
sequence
generation
Allocation
concealment Blinding Incomplete
outcome data
Selective
reporting
Free of other
bias
Summary
assessments
Zhao 2007 [19]U U H U U H H
Yan et al. [20]
2009 UUHUUHH
Wang and Hou
2010 [21] UUHUUHH
Yang et al. 2010
[22] UUHUUHH
Ge et al. 2010
[23] UUHUUHH
Ge and Zhu
2009 [24] UUHHUHH
Hu et al. 2009
[25] UUHUUHH
Pei and Chen
2009 [26] UUHUUHH
Zuo and Hou
2009 [27] UUHUUHH
Song 2008 [28]U U H H U H H
Xu 2008 [29]U U H L U H H
Huang et al.
2008 [30] UUHUUHH
Li et al. 2008
[31] UUHUUHH
Hua et al. 2007
[32] LLH UU H H
Wang et al. 2007
[33] UUHUUHH
Ma et al.
2007[34] UUHUUHH
X. G. Zhang and
Y. M. Zhang
2006 [35]
UUHUUHH
Zhang et al.
2006 [36] UUHHUHH
Liu and Yang
2010 [37] UUHHUHH
Yang and Cai
2009 [38] UUHUUHH
Bai and Ding
2007 [39] UUHHUHH
Fang and Wang
2007 [40] UUHHUHH
Jiang 2004 [41]U U H U U H H
Qi and Qu 2008
[42] UUHUUHH
Han and Wang
2011 [43] UUHHUHH
L: low risk of bias, U: unclear, H: high risk of bias.Evidence-Based Complementary and Alternative Medicine 7
SS Routine Risk ratio Risk ratio
Study or subgroup
Events Total Events Total Weight M-H, ﬁxed, 95% CI M-H, ﬁxed, 95% CI
Zhao 2007 36 39 37 39 100% 0.97 [0.87, 1.09]
Total (95% CI) 39 39 100% 0.97 [0.87, 1.09]
Heterogeneity: not applicable
Test for overall eﬀect: Z = 0.46 (P = 0.64) Favors routine Favors SS
0.5 1 2
Figure 3: SS versus Isosorbide, outcome: ECG.
Routine Risk ratio Risk ratio
Study or subgroup Events Total Events Total Weight M-H, ﬁxed, 95% CI M-H, ﬁxed, 95% CI
Bai and Ding 2007 34 40 24 40 3.3% 1.42 [1.07, 1.88]
Fang and wang 2007 49 60 31 60 4.3% 1.58 [1.20, 2.08]
Ge and Zhu 2009 22 24 17 24 2.4% 1.29 [0.97, 1.72]
Ge 2010 et al. 27 30 20 30 2.8% 1.35 [1.02, 1.79]
Han and wang 2011 95 96 79 90 11.4% 1.13 [1.04, 1.22]
Hu 2009 et al. 70 74 60 74 8.4% 1.17 [1.03, 1.32]
Hua 2007 et al. 51 56 41 56 5.7% 1.24 [1.04, 1.49]
Huang 2008 et al. 100 110 76 110 10.6% 1.32 [1.15, 1.51]
Jiang 2004 70 80 41 76 5.9% 1.62 [1.30, 2.03]
Liu and Yang 2010 45 50 35 50 4.9% 1.29 [1.05, 1.58]
Ma 2007 et al. 26 30 22 29 3.1% 1.14 [0.89, 1.46]
Pei and Chen 2009 29 36 23 35 3.3% 1.23 [0.92, 1.64]
Song 2008 50 53 42 52 5.9% 1.17 [1.01, 1.35]
Wang 2007 et al. 22 25 14 25 2.0% 1.57 [1.08, 2.29]
Wang and Hou 2010 46 50 40 50 5.6% 1.15 [0.98, 1.35]
Yang and Cai 2009 28 32 20 32 2.8% 1.40 [1.04, 1.89]
Yang 2010 et al. 30 32 23 32 3.2% 1.30 [1.03, 1.65]
42 46 34 48 4.6% 1.29 [1.05, 1.58]
Zhang 2006 et al. 25 26 22 26 3.1% 1.14 [0.95, 1.36]
X.G. Zhang and Y.M. Zhang 2006 26 30 19 30 2.6% 1.37 [1.01, 1.86]
Zuo and Hou 2009 39 42 30 41 4.2% 1.27 [1.04, 1.56]
Total (95% CI) 1022 1010 100.0% 1.28 [1.23, 1.34]
926 713
Test for overall eﬀect: Z = 11.13 (P < 0.00001)
Total events
Yan 2009 et al.
SS + routine
Favors routine Favors SS + routine
0.5 1 2 Heterogeneity: χ2 = 27.31, df = 20 (P = 0.13); I2 = 27%
Figure 4: SS + routine therapy versus routine therapy, outcome: clinical symptom improvement.
one or more key domains within a study is suﬃcient to aﬀect
theinterpretationofresultsacrossthestudies.Disagreements
were resolved by discussion and by adjudicated by a third
reviewer (Jiang) when necessary.
2.5. Data Analysis. Our comparisons included SS versus
western medication and SS plus routine therapy versus rou-
tinetherapy.Wereportedriskratio(RR)and95%conﬁdence
intervals (CI) for the pooled binary data, and mean diﬀer-
ences (MD) for continuous data. The test of homogeneity
was used with a signiﬁcance level of 0.1. We also used the I-
square statistic to assess the heterogeneity. Publication bias
was assessed by the funnel plot. We performed sensitivity
analysis by using diﬀerent statistical methods (ﬁxed-eﬀect
and random-eﬀects models) for combining data to explore
the inﬂuence of study quality on eﬀect size.
3. Results
A total of twenty-ﬁve trials [19–43], involving 2,377 par-
ticipants with unstable angina deﬁned as new onset (≤2
months) exertional angina of at least Canadian Cardio-
vascular Society Classiﬁcation (CCSC) class III in severity,
signiﬁcant recent increase in frequency and severity of
angina, or angina at rest, proved eligible (Figure 1).
All 25 trials were conducted in China. The treatment
duration ranged from 1 to 4 weeks, and the dose from 40 to
80mg per day. One trial [34] compared SS injection versus
isosorbide mononitrate. The other 24 trials compared SS
injection plus western medications versus western medica-
tions alone. There were no placebo controlled studies. SS
injection is given diluted at the point of treatment in 20mL
25% glucose injection for intramuscular administration8 Evidence-Based Complementary and Alternative Medicine
Routine Risk ratio Risk ratio Study or subgroup
Events Total Events Total Weight M-H, ﬁxed, 95% CI M-H, ﬁxed, 95% CI
Bai and Ding 2007 28 40 15 40 4% 1.87 [1.19, 2.92]
Ge 2010 et al. 25 30 19 30 5% 1.32 [0.96, 1.80]
Hu 2009 et al. 65 74 57 74 15% 1.14 [0.98, 1.33]
Hua 2007 et al. 49 56 40 56 10.6% 1.23 [1.01, 1.49]
Huang 2008 et al. 100 110 81 110 21.4% 1.23 [1.09, 1.40]
Ma 2007 et al. 25 30 19 29 5.1% 1.27 [0.93, 1.73]
Wang 2007 et al. 21 25 13 25 3.4% 1.62 [1.07, 2.44]
Wang and Hou 2010 41 50 38 50 10% 1.08 [0.88, 1.32]
Yang and Cai 2009 27 32 25 32 6.6% 1.08 [0.85, 1.37]
Yang 2010 et al. 29 32 19 32 5% 1.53 [1.12, 2.08]
24 46 25 48 6.5% 1.00 [0.68, 1.48]
Zhang 2006 et al. 23 26 17 26 4.5% 1.35 [0.99, 1.85]
X.G. Zhang and Y.M. Zhang 2006 20 30 11 30 2.9% 1.82 [1.07, 3.10]
Total (95% CI) 581 582 100% 1.26 [1.18, 1.35]
Total events 477 379
Yan 2009 et al.
Test for overall eﬀect: Z = 6.57 (P < 0.00001)
SS + routine
Favors routine Favors SS + routine
0.2 1 5 Heterogeneity: χ2 = 14.99, df = 12 (P = 0.24); I2 = 20%
Figure 5: SS + routine therapy versus routine therapy, outcome: ECG.
SS + routine Routine Mean difference Mean difference
Study or 
subgroup Mean SD Total Mean SD Total Weight IV, ﬁxed, 95% CI IV, ﬁxed, 95% CI
Jiang 2004 11.0 9.14 80 8.5 9.35 76 2.7%
Wang 2007 et al. 3.11 3.38 25 0.35 3.25 25 6.8% 2.76 [0.92, 4.60]
Xu and Su 2008 7.43 1.05 37 5.07 2.27 37 35.4% 2.36 [1.55, 3.17]
Yang 2010 et al. 7.62 1.23 32 5.78 1.4 32 55.1% 1.84 [1.19, 2.49]
Total (95% CI) 174 170 100% 2.1 [1.63, 2.58]
Test for overall eﬀect: Z = 8.61 (P < 0.00001) Favors routine Favors SS + routine
−50 5
2.50 [−0.40, 5.40]
Heterogeneity: χ2 = 1.59, df = 3 (P = 0.66); I2 = 0%
Figure 6: SS + routine therapy versus routine therapy, outcome: C-reaction Protein.
or in 250–500mL 5% glucose injection for intravenous
administration. The dosage and administration are not
clearly described in every study (Table 1).
Two trials [33, 35] reported data on mortality. Most trials
reported improvement of clinical symptoms and ECG.
All studies were at high risk of bias (Table 2). One trial
[33] described the method of randomization in detail, and
the method was also appropriate. All the other studies did
not report information on the allocation concealment. One
trial [37] mentioned it is a single-blinded study, and none
were double blinded. Loss to followup was recorded in
none of the studies. No studies conducted intention-to-treat
analysis.
3.1. SS versus Western Medications. One trial [34]c o m p a r e d
SS alone versus western medicine. There were no signiﬁcant
diﬀerences in improvement of clinical symptoms (RR 1.00,
95%CI0.90to1.11,Figure 2) andimprovementinECG (RR
0.97, 95% CI 0.87 to 1.09, Figure 3).
3.2. SS + Western Medications versus Western Medications.
Two trials [33, 35] comparing SS plus western medications
versus western medications reported only one sudden death
in the western medication group [33] (RR 0.50; 95% CI 0.02
to 12.13).
Sodium plus western medications achieved statistically
signiﬁcant improvement of clinical symptoms than western
medications alone (RR 1.28, 95% CI 1.23 to 1.34, Figure 4),
and improvement of ECG (RR 1.26, 95% CI 1.18 to 1.35,
Figure 5), C-reaction protein (mean diﬀerence 2.10, 95% CI
1.63to2.58,Figure 6),andIL-6(meandiﬀerence −3.85,95%
CI −4.10 to −3.60, Figure 7).
Of the 25 trials, 7 reported adverse events. In the rou-
tine treatment group, adverse reactions included headache,
dizziness,facialﬂushing,fatigue,andbruisesatinjectionsite.
Totally 32 cases were reported. In the SS + routine treatment
group, adverse reactions included facial ﬂushing, dizziness,
bruises, tension or swell at injection site, blood in sputum,
and gum bleeding. Totally 13 cases were reported. No severe
adverse events were found and no treatment was stopped
because of adverse events.
Because the funnel plot seems symmetric, the possibility
that the result of this review might be misled by publication
bias is likely to be little (Figure 8).Evidence-Based Complementary and Alternative Medicine 9
SS + routine Routine Mean difference Mean difference Study or 
subgroup Mean SD Total Mean SD Total Weight IV, ﬁxed, 95% CI IV, ﬁxed, 95% CI
Xu and Su 2008 5.25 0.22 37 9.1 0.88 37 74.2%
Yang 2010 et al. 5.45 0.94 32 9.31 1.08 32 25.8%
Total (95% CI) 69 69 100%
−3.85 [−4.14, −3.56]
−3.86 [−4.36, −3.36]
−3.85 [−4.1, −3.6]
Test for overall eﬀect: Z = 29.99 (P < 0.00001) Favors routine Favors SS + routine
−50 5 Heterogeneity: χ2 = 0, df = 1 (P = 0.97); I2 = 0%
Figure 7: SS + routine therapy versus routine therapy, outcome: IL-6.
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Figure 8: Funnel plot of comparison: SS plus routine therapy versus routine therapy, outcome: clinical symptom improvement. (Each dot
represents one study. All the dots are conforming to a triangular form, meaning that publication bias is low).
4. Discussion
SS injection appeared an eﬀective and safe treatment option
for unstable angina pectoris. The present results showed that
SS plus routine therapies appear to be more eﬀective than
western medications alone.
However, trials are at high risk of bias, making the ﬁnd-
ings less compelling. Except for one trial, none of the other
trials reported the method of randomization. Although all
trials claimed randomization, they failed to provide enough
information to judge whether the randomization procedures
had been carried out properly. No multicenter, large-scale
RCTs were identiﬁed. No dropouts and withdrawals were
described. No placebo control was used and none of the
trials were of double blind. Routine therapy varied from trial
to trial. The dosage and administration of control and trial
therapies are not clearly described in every study.
The main outcomes from the included 25 trials were the
improvement of clinical symptoms and ECG. The primary
outcome measure was reported in only two trials. There is
lack of data from RCTs on clinically relevant outcomes from
long-term followup such as mortality and health-related
quality of life.
18 out of 25 trials referred to observation of side eﬀects.
There were less side events in the SS injection group. None of
the events were severe and no patients dropped out because
of the side eﬀects. SS injection appears to be relatively safe.
We have conducted comprehensive searches. However,
onlytrialspublishedinEnglishandChinesewereindentiﬁed.
Unpublished studies were found but none of them met the
inclusioncriteria.Sinceallofthetrialswereofsmallsizewith
positive results and were conducted China, geographic biases
may be induced.
The poor evidence does not allow any conclusion
regarding the eﬀectiveness of SS, and none of the included
trials were ideally suited to investigate the eﬀectiveness of SS
in treating unstableangina. While SSis a widely used therapy
forunstableanginainChina,theresultsofthepresentreview
suggest that high-quality controlled trials are required for
assessment.
5. Conclusions
Compared with western medications alone, SS combined
with western medications was of more beneﬁts for patients
with unstable angina with fewer side eﬀects. However, the
methodological concerns, such as allocation concealment,
lack of blinding, lack of information on the hazards of
treatment,andtheriskofpublicationbias,makeitdiﬃcultto
determinetheroleofSSinjectioninmanagementofunstable
angina.
Considering the strength of the evidence, more
rigorously designed, randomized double-blind placebo-
controlled trials are required for assessing the eﬀects of SS
injection before SS injection can be recommended routinely.
Some aspects should be specially considered, including
methodological improvement (such as details on the
methods of randomization and the allocation concealment,
blinding and placebo control, dropouts and withdrawals),
adverse reactions, and reporting clinically outcomes from10 Evidence-Based Complementary and Alternative Medicine
long-term followup such as mortality and health-related
quality life.
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